Benzinga | Sep 25, 2020 09:04AM EDT

TherapeuticsMD Says Is On Track To Meet Or Exceed Q3 Sales Of $15.1M; Says 'Underlying retail and wholesale demand for ANNOVERA is strong and growing' But 'believes industry prescription tracking databases are not accurately tracking ANNOVERA'

-Company believes industry prescription tracking databases are not accurately tracking ANNOVERA(r)-

-Underlying retail and wholesale demand for ANNOVERA is strong and growing-

-Company experiencing record retail and wholesale growth for ANNOVERA-

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that the Company is on track to meet or exceed third quarter 2020 total net revenue consensus of $15.1 million. For the Company's ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) product, the Company has seen increases in orders to wholesalers, retail pharmacies and online distributors throughout the quarter that are greater than the patient demand numbers being reported by industry prescription tracking databases. In addition, weekly inventory on hand reported by wholesalers remains consistent over the quarter, indicating that inventory levels in the channel are not increasing. The Company believes that industry prescription tracking databases are not accurately reflecting the consistent underlying demand for ANNOVERA seen in orders to wholesalers, retail pharmacies and online distributors. The Company is working with industry prescription tracking databases to identify why this demand is not identified in their published numbers. The Company believes it is well positioned to meet or exceed third quarter 2020 total net revenue consensus, putting the Company on a strong trajectory for the fourth quarter.